HIV‐1AIDSCommon single-nucleotide variation in the host accounts for 25% of the variability in the plasma levels of HIV during the clinical latency stage (viral load set point). However, the role of rare variants and copy number variants remains relatively unexplored. Previous work has ...
PURPOSE OF REVIEW: To provide an overview of the initial experiences with the use of latency-reversing agents (LRAs) in clinical trials in HIV and to discuss and contrast results arising from these studies. RECENT FINDINGS: Although the clinical administration of histone deacetylase inhibitors (HDAC...
the effect may occur after a long period of latency, sometimes lasting years. An example is the hormone diethylstilbestrol which was given to pregnant women. Some 18–20 years later, the daughters born to the treated women presented an increased rate of genital cancer ...
EBT-101 is a CRISPR-based therapy being developed as a potential cure for HIV– EBT-101 is being developed as a potential cure for HIV-1 by targeting latently integrated proviral HIV DNA. Latency is a...
No Evidence for Association of β‐Defensin Genomic Copy Number with HIV Susceptibility, HIV Load during Clinical Latency, or Progression to AIDS Hollox EJ (2017) No evidence for association of beta-defensin genomic copy number with HIV susceptibility, HIV load during clinical latency, or ...
Mtbavoids or tolerates it. The lack of antigen presentation affects a lymphocyte-mediated immune response, mainly a T-mediated one. Granuloma formation is designed to contain and eliminateMtb; this is used by the pathogen to remain in a state of latency while waiting to become able to colon...
(HIV) is associated with immunosuppression that contributes to the development of AIDS-defining cancers (specifically, Kaposi sarcoma, aggressive B cell non-Hodgkin lymphoma and cervical cancer). Given that an adaptive T cell-mediated immune response is crucial for the control of viral infections, ...
The ability of HIV to establish a latent infection causes life-long virus persistence, even after long-term highly active antiretroviral therapy (HAART). The role that latency is playing in preventing the clearance of the virus infection has become evident in recent years. Patients who have been...
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to caus...
Risk factors for bacterial pneumonia include advanced immunosuppression, interruption of antiretroviral therapy, smoking, intravenous drug use and pre-existing lung disease. Bacterial pneumonia can occur at any stage of HIV infection but tends to occur frequently in individuals with advanced immunosuppression...